These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 24638267)
1. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267 [TBL] [Abstract][Full Text] [Related]
2. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? Ou D; Levy A; Blanchard P; Nguyen F; Garberis I; Casiraghi O; Scoazec JY; Janot F; Temam S; Deutsch E; Tao Y Oral Oncol; 2016 Aug; 59():50-57. PubMed ID: 27424182 [TBL] [Abstract][Full Text] [Related]
3. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis. Tang WH; Sun W; Long GX Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005 [TBL] [Abstract][Full Text] [Related]
4. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas. Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345 [TBL] [Abstract][Full Text] [Related]
5. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan. Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008 [TBL] [Abstract][Full Text] [Related]
6. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial. Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993 [TBL] [Abstract][Full Text] [Related]
7. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study. Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685 [TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study. Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491 [TBL] [Abstract][Full Text] [Related]
9. Chemoradiotherapy with weekly cisplatin 40 mg/m(2) in 103 head-and-neck cancer patients: a cumulative dose-effect analysis. Steinmann D; Cerny B; Karstens JH; Bremer M Strahlenther Onkol; 2009 Oct; 185(10):682-8. PubMed ID: 19806334 [TBL] [Abstract][Full Text] [Related]
10. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer. Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976 [TBL] [Abstract][Full Text] [Related]
11. A comparison of concurrent cisplatin versus cetuximab with radiotherapy in locally-advanced head and neck cancer: A bi-institutional analysis. Stokes WA; Sumner WA; Breggren KL; Rathbun JT; Raben D; McDermott JD; Gan G; Karam SD Rep Pract Oncol Radiother; 2017; 22(5):389-395. PubMed ID: 28808428 [TBL] [Abstract][Full Text] [Related]
12. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab. Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704 [TBL] [Abstract][Full Text] [Related]
13. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Dornoff N; Weiß C; Rödel F; Wagenblast J; Ghanaati S; Atefeh N; Rödel C; Balermpas P Strahlenther Onkol; 2015 Aug; 191(8):656-64. PubMed ID: 26004121 [TBL] [Abstract][Full Text] [Related]
14. A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN). Grover S; Mitra N; Wan F; Lukens JN; Sharma S; Bauman J; Masroor F; Cohen RB; Desai A; Algazy K; Alonso-Basanta M; Ahn P; Kevin Teo BK; Chalian AA; Weinstein GS; O'Malley BW; Lin A Am J Clin Oncol; 2016 Oct; 39(5):522-7. PubMed ID: 27441910 [TBL] [Abstract][Full Text] [Related]
15. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma. Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Egloff AM; Lee JW; Langer CJ; Quon H; Vaezi A; Grandis JR; Seethala RR; Wang L; Shin DM; Argiris A; Yang D; Mehra R; Ridge JA; Patel UA; Burtness BA; Forastiere AA Clin Cancer Res; 2014 Oct; 20(19):5041-51. PubMed ID: 25107914 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma. Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954 [TBL] [Abstract][Full Text] [Related]
19. Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis. Balermpas P; Bauer C; Fraunholz I; Ottinger A; Wagenblast J; Stöver T; Seitz O; Fokas E; Rödel C; Weiss C Strahlenther Onkol; 2014 Mar; 190(3):256-62. PubMed ID: 24413895 [TBL] [Abstract][Full Text] [Related]
20. Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis. Huang J; Zhang J; Shi C; Liu L; Wei Y BMC Cancer; 2016 Aug; 16(1):689. PubMed ID: 27565887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]